A benefit for KLRG1 blockade in mouse models was demonstrated in 2019 and again in 2021 [10, 11], with KLRG1 and PD-1 blockade producing supra-additive benefits in the B16F10 mouse melanoma model. This evidence concerns the gene KLRG1 and melanoma.